Abstract
Alaska is the largest geographic state in the United States with the lowest population density and a mix of urban centers and isolated rural communities. The differences in population dynamics in Alaska from the contiguous United States may have contributed to a unique pattern of emergence and spread of SARS-CoV-2 variants observed in early 2021. Here we examined 2,323 virus genomes from Alaska and 278,635 virus genomes from the contiguous United States collected between the first week of December 2020 through the last week of June 2021. We focused on this timeframe because of the notable emergence and spread of the SARS-CoV-2 lineage B.1.1.519 observed in Alaska. We found that this variant was consistently detected in Alaska from the end of January through June of 2021 with a peak prevalence in April of 77.9% unlike the rest of the United States with a peak prevalence of 4.6%. In Alaska, the earlier emergence of B.1.1.519 coincided with a later peak of Alpha (B.1.1.7) when compared to the rest of the United States. We also observed differences in the composition of lineages and variants over time between the two most populated regions of Alaska. Although there was a modest increase in COVID-19 cases during the peak incidence of B.1.1.519, it is difficult to disentangle how social dynamics conflated changes in COVID-19 during this time. We suggest that the viral characteristics, such as amino acid substitutions in the spike protein, and a founder effect likely contributed to the unique spread of B.1.1.519 in Alaska.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Work presented here was supported by Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) from the Centers for Disease Control and Prevention and a supplement award to Alaska INBRE, an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number 2P20GM103395.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves only openly available SARS-CoV-2 genome sequence data collected from humans, which can be obtained from GISAID at gisaid.org and GenBank at https://www.ncbi.nlm.nih.gov/sars-cov-2/. Metadata on the number of cases for Alaska is available on the Alaska COVID-19 Summary Dashboard (https://covid19.alaska.gov/) and specifically Cases Data B (https://www.arcgis.com/sharing/rest/content/items/ba85c5899fd3440cad7c2d3406f2fde4/data)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this study are available online at GISAID (https://www.gisaid.org/) and NCBI GenBank (https://www.ncbi.nlm.nih.gov/sars-cov-2/). Metadata on the number of cases for Alaska is available on the Alaska COVID-19 Summary Dashboard (https://covid19.alaska.gov/)
